DE69625239D1 - Verfahren zur krebsdetektion - Google Patents

Verfahren zur krebsdetektion

Info

Publication number
DE69625239D1
DE69625239D1 DE69625239T DE69625239T DE69625239D1 DE 69625239 D1 DE69625239 D1 DE 69625239D1 DE 69625239 T DE69625239 T DE 69625239T DE 69625239 T DE69625239 T DE 69625239T DE 69625239 D1 DE69625239 D1 DE 69625239D1
Authority
DE
Germany
Prior art keywords
glucuronide
fraction
2meoe1
16ohe1
2ohe1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625239T
Other languages
English (en)
Other versions
DE69625239T2 (de
Inventor
L Klug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuna Care Corp
Original Assignee
Immuna Care Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuna Care Corp filed Critical Immuna Care Corp
Publication of DE69625239D1 publication Critical patent/DE69625239D1/de
Application granted granted Critical
Publication of DE69625239T2 publication Critical patent/DE69625239T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Steroid Compounds (AREA)
DE69625239T 1995-09-19 1996-09-19 Verfahren zur krebsdetektion Expired - Lifetime DE69625239T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US396695P 1995-09-19 1995-09-19
PCT/US1996/015096 WO1997011374A1 (en) 1995-09-19 1996-09-19 Method of cancer detection

Publications (2)

Publication Number Publication Date
DE69625239D1 true DE69625239D1 (de) 2003-01-16
DE69625239T2 DE69625239T2 (de) 2003-11-06

Family

ID=21708443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625239T Expired - Lifetime DE69625239T2 (de) 1995-09-19 1996-09-19 Verfahren zur krebsdetektion

Country Status (8)

Country Link
US (1) US5854009A (de)
EP (1) EP0866969B1 (de)
AT (1) ATE229185T1 (de)
AU (1) AU7114696A (de)
CA (1) CA2232380C (de)
DE (1) DE69625239T2 (de)
ES (1) ES2187674T3 (de)
WO (1) WO1997011374A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
AU781303B2 (en) * 1999-10-14 2005-05-12 University Of Melbourne, The Estradiol conjugates and uses thereof
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US20060088475A1 (en) * 2004-05-10 2006-04-27 Northwestern University Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
CA2971968C (en) * 2007-10-24 2019-08-13 Biomarker Strategies, Llc Improved methods and devices for cellular analysis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5833162A (ja) * 1981-08-21 1983-02-26 Eiken Kagaku Kk エストリオ−ル−１６α−グルクロナイド測定用抗原およびその製造法
JPS5871460A (ja) * 1981-10-23 1983-04-28 Eiken Kagaku Kk エストラジオ−ル−３−グルクロナイド測定用抗原およびその製造法
JPS5871459A (ja) * 1981-10-23 1983-04-28 Eiken Kagaku Kk エストリオ−ル−３−グルクロナイド測定用抗原およびその製造法
EP0114614A2 (de) * 1983-01-25 1984-08-01 Abbott Laboratories Bestimmung von Steroidhormon-Glucuroniden
AU641409B2 (en) * 1989-07-17 1993-09-23 Rockefeller University, The Method and materials for detecting pathology from alterations in estrogen metabolism
US5663054A (en) * 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay

Also Published As

Publication number Publication date
WO1997011374A1 (en) 1997-03-27
CA2232380A1 (en) 1997-03-27
US5854009A (en) 1998-12-29
CA2232380C (en) 2009-02-03
EP0866969A1 (de) 1998-09-30
ATE229185T1 (de) 2002-12-15
EP0866969B1 (de) 2002-12-04
AU7114696A (en) 1997-04-09
DE69625239T2 (de) 2003-11-06
ES2187674T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
WO1996007761A3 (en) Method for testing for mutations in dna from a patient sample
ATE402269T1 (de) Methoden und testsätze für annäherungstest
NZ306051A (en) Testing using electrochemiluminescence
ATE496288T1 (de) Gleichzeitige mehrfachanalyse klinischer proben
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
CA2214488A1 (en) Determination of cpsa
CA2235316A1 (en) A method for detecting antipolymer antibodies and a diagnostic test kit for use in aiding the diagnosis of silicone related diseases (srd)
IL142971A0 (en) S100 proteins and autoantibodies as serum markers for cancer
DE69625239D1 (de) Verfahren zur krebsdetektion
Chen et al. Advances in HER2 testing
EP1214447B8 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
DE69839876D1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
CA2346406A1 (en) Detection of pleiotrophin
KR20150004491U (ko) 비인두암 진단 방법 및 진단 장치
DE69725118D1 (en) Reagentien für tests für mycophenolsäure
WO2001091629A3 (en) Methods for detecting dna damage and screening for cancer therapeutics
ATE365921T1 (de) Immunologische zusammensetzung zum nachweis von blasenkrebs und verfahren zu ihrer verwendung
NO20016080D0 (no) Analyse
EP1636587A4 (de) Einen für menschliches protoonkogenes protein spezifischen antikörper enthaltender diagnostischer kit für leberzirrhose
JPH0996635A (ja) 多項目尿試験紙
DE69033072T2 (de) Verfahren und Mittel zum Nachweis von Krankheitszuständen aus Änderungen im Östrogenstoffwechsel
DE59910326D1 (de) Verwendung derivatisierter Reagenzien in Chemilumineszenz- und Elektrochemilumineszenz-Nachweisverfahren
DE69929817D1 (de) Verfahren zur aktivitätsbestimmung einer substanz mittels eines funktionellen in vitro tests
WO2001086292A3 (en) Ipg assay
CA2296042A1 (fr) Methodes et kits pour le diagnostic de la maladie d'alzheimer